FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年9月30日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | 本月底法定/註冊股本總額： RMB 103,568,013 備註： 因本公司是於中華人民共和國註冊成立的公司，「法定股本」之概念不適用於本公司，上 ...

通知指出，为深入贯彻健康中国、制造强国战略部署，加快推进高端医疗装备创新发展，开展新技术新 产品新场景大规模应用，现就 2025 年度高端医疗装备推广应用项目申报工作有关事项通知如下：面向 高端医疗装备重点产品和典型场景，遴选一批技术创新水平与临床应用水平处于全国前列，对医工协同 创新、中试验证、临床研究、迭代升级与推广应用等具有较强引领带动作用的项目。本年度重点开展 5 类重点产品和 4 类典型场景的推广应用。 智通财经APP获悉，工业和信息化部办公厅 、国家卫生健康委办公厅、 国家药监局综合和规划财务司 发布关于开展 2025 年高端医疗装备推广应用项目申报工作的通知。 招商证券国际发布研报称，2025年上半年，内地医疗器械行业整体收入同比跌3.8%，归母净利润同比 跌12.8%;扣非净利润同比跌14.5%。第二季单季收入同比跌5.5%，归母净利润同比跌20.3%，扣非净利 润同比降25%。 该行以港股和A股上市的129家医疗器械公司为样本，经过分析发现上半年约53%的公司收入实现同比 增长，增速超20%占比16%，增速处于0-20%区间占比37%。 该行认为，经历过疫情及国内集采双重政策扰动后，整体器械 ...

Beijing Airdoc Technology Co., Ltd. (A joint stock company incorporated in the People's Republic of China with limited liability) （於中華人民共和國註冊成立的股份有限公司） Stock Code 股份代號：2251 Interim Report 中 期 報 告 2025 2025 CONTENTS 目 錄 2 Corporate Information 公司資料 6 Financial Summary 財務概要 7 Management Discussion and Analysis 管理層討論與分析 44 Other Information 其他資料 65 Independent Review Report 獨立審閱報告 67 Interim Condensed Consolidated Statement of Profit or Loss 中期簡明綜合損益表 68 Interim Condensed Consolidated Statement of Comprehensiv ...

8 月 28 日，上海和平眼科医院成功举办了鹰瞳科技眼科PACS系统验收及眼底AI人工智能平台启动仪 式。鹰瞳Airdoc副总裁赵雷一行受邀出席，与院方医护人员共同见证这一重要时刻，上海和平眼科医院 在眼科智能化诊疗领域开启新的篇章。 上海和平眼科医院x鹰瞳Airdoc：携手打造眼科信息化标杆 在本次仪式之前，上海和平眼科医院已通过鹰瞳PACS系统部署，实现了眼科设备全场景接入、影像数 据全流程管理、诊疗服务全链条优化，破解了传统模式下设备孤岛、影像分散、效率低下、数据沉睡等 难题。 华厦眼科医院集团领导张昊志在致辞中着重指出，上海和平眼科医院作为集团在华东地区战略布局的关 键支点与中心枢纽医院，成功部署并出色应用鹰瞳PACS系统，不仅是其在医疗数字化转型浪潮中主动 拥抱变革、积极探索医疗人工智能与信息化深度融合路径的有力实践，更彰显了其以患者为中心，通过 技术创新优化诊疗流程、提升诊断精准度的坚定决心。这一成功实践为集团内其他医院在医疗科技应 用、服务模式创新等方面提供了极具参考价值与可复制性的宝贵经验，将有力推动集团整体医疗服务能 级迈向新高度。 上海和平眼科医院总经理胡剑徽在致辞中表示，人工智能技术正在 ...

Core Viewpoint - Airdoc Technology (2251.HK) reported a turnaround in profitability for the first half of 2025, achieving a net profit of 443,000 RMB, with treatment business revenue accounting for 31.6% of total revenue. The company continues to drive AI applications and deepen its integrated diagnosis and treatment strategy, laying a solid foundation for long-term development through cost reduction, efficiency improvement, and product innovation [1][10]. Group 1: AI Product Lines and Performance - The retinal detection AI product line detected 3.3 million UVs in the first half of 2025, a year-on-year increase of 11.4%, with a cumulative total of 100,000 significant positive cases identified, contributing to reduced long-term disease burden for individuals and families [2][12]. - Active service points for the retinal detection AI product reached 7,180, a 20.7% increase year-on-year, with 346 active locations in grade hospitals, up 41.8% [2][11]. - The myopia prevention AI product line recorded 2.812 million UVs, a 68.1% increase, serving 58,000 users, while the visual training AI had 1.026 million UVs, an 11.6% increase, with a total of 36,000 users served [3][15][16]. Group 2: Technological Advancements - Airdoc's myopia prevention AI product has integrated the Wanyu large model, transforming it into a 'family optometrist' with autonomous decision-making capabilities, enhancing the efficacy of photobiological modulation therapy (PBMT) [4][23]. - The new portable fundus camera (AI-FD16U) was approved in January 2025, weighing only 1.3 kg and featuring touchscreen and voice interaction capabilities [4][25]. - The Wanyu medical large model was upgraded in February 2025, applying generative AI technology across various fields, including AI fundus detection and AI myopia prevention [4][27]. Group 3: Global Expansion and Research Achievements - Airdoc is accelerating its global layout, with AI product service points covering regions including the EU, Singapore, Thailand, and several other countries, increasing overseas market revenue share to 12.3% [6][21]. - Research collaborations have led to significant publications, including a deep learning model for identifying mild cognitive impairment in coronary artery disease patients, published in the journal "Heart," and a skin cancer early screening system published in "Nature Medicine," improving detection accuracy by 11% [6][31][33]. - The company has received 13 new patents, bringing the total to 283, including a digital occlusion therapy that addresses patient compliance issues [5][35].

FF301 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | H | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02251 | 說明 | H股 | | | | | | | | | 法定/註冊股份數目 | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | | 增加 / 減少 (-) | | | 0 | | | RMB | | 0 | | 本月底結存 | | | 103,568,013 | RMB | | 1 RMB | | 103,568,013 | 本月底法定/註冊股本總額： RMB 103,568,013 備註： 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 北京鷹瞳科技發展股份有限公司 (「本 ...

Major Events - Sihuan Pharmaceutical Holdings Group Ltd. successfully administered the first human dose of the new radiopharmaceutical conjugate drug 3D1015 [1] - Shenzhen International's joint venture Shenzhen Airlines plans to raise a total of 16 billion yuan in a phased capital increase [1] - Kangzheng Pharmaceutical received clinical trial approval for its innovative oral small molecule JAK1 inhibitor Povorcitinib for indications of vitiligo and suppurative hidradenitis [1] - Ruihe Digital signed a framework agreement with Tielin Superlight Technology to jointly advance the business of real-world asset tokenization [1] - Zhongxu Future will operate and launch a new mobile game "Miracle MU" titled "New Moon Continent" [1] Financial Performance - Noah Holdings reported a net profit attributable to shareholders of 179 million yuan for Q2, a year-on-year increase of 79% driven by strong growth in investment product distribution [1] - Trip.com Group reported a net profit of 4.846 billion yuan for Q2, an increase of 26.43% year-on-year [1] - Shijiazhuang Pharmaceutical Group announced a mid-year profit attributable to equity holders of approximately 283.5 million HKD, a year-on-year decrease of about 58.7% [1] - Zhongsheng Holdings reported a mid-year profit attributable to shareholders of 1.011 billion yuan, a decrease of 36% year-on-year [1] - SF Express City reported an adjusted net profit of approximately 160 million yuan, a year-on-year increase of 139% [1] - Baidu's subsidiary reported a mid-year profit attributable to shareholders of 47.999 million yuan, returning to profitability [1] - Li Auto reported a net profit of 1.093 billion yuan for Q2, a decrease of 0.91% year-on-year [1] - Shanghai Industrial Holdings reported a mid-year profit attributable to shareholders of 1.042 billion HKD, with an interim dividend of 0.42 HKD per share [1] - Beijing Holdings reported a mid-year profit attributable to shareholders of 3.404 billion yuan, an increase of 8.07% year-on-year [1] - Qingdao Port reported a net profit of 2.842 billion yuan, a year-on-year increase of 7.58% [1] - New China Life Insurance reported a net profit of 14.799 billion yuan, a year-on-year increase of 33.5% [1] - China Galaxy Securities reported a net profit of 6.488 billion yuan, a year-on-year increase of 47.86% [1] - China Taiping reported a 12.2% increase in shareholder profit, with a nearly 23% high growth in life insurance new business value [1] - China Resources Gas reported a mid-year profit attributable to shareholders of 2.403 billion HKD, a year-on-year decrease of 30.5% [1] - SF Holding reported a net profit of 5.738 billion yuan, a year-on-year increase of 19.37%, with volume growth exceeding the overall express delivery industry [1] - SMIC reported a net profit of approximately 320 million USD, a year-on-year increase of 35.6% [1] - SenseTime reported a revenue growth of 35.6% year-on-year, reaching 2.358 billion yuan [1] - BeiGene reported a net profit of 95.59 million USD, returning to profitability [1] - Fubo Group reported a mid-year net profit exceeding 100 million, driven by AI [1] - CITIC Securities reported a net profit of 13.719 billion yuan, a year-on-year increase of 29.79% [1] - Huadian International Power reported a net profit of 3.904 billion yuan, a year-on-year increase of 13.15% [1] Additional Financial Performance - Zhou Hei Ya reported a mid-year profit attributable to shareholders of 108 million yuan, a year-on-year increase of 228% [2] - Haitian Flavoring reported a net profit of 3.91 billion yuan, a year-on-year increase of 13.3% [2] - Dasheng Holdings reported a mid-year adjusted net profit growth of 79.6% driven by store expansion and membership growth [2] - CITIC Securities reported a net profit of 4.509 billion yuan, a year-on-year increase of 57.77% [2] - Huitongda reported a mid-year profit attributable to shareholders of 13.9 million yuan, a year-on-year increase of 10.81% [2] - Yunfeng Financial reported a mid-year profit attributable to shareholders of 486 million HKD, a year-on-year increase of 142.04% [2] - Jiufang Zhitu reported a mid-year profit attributable to shareholders of 865 million yuan, returning to profitability [2] - Air China reported a net loss of approximately 1.806 billion yuan, a year-on-year narrowing of 35.11% [2] - ZTE reported a net profit of approximately 5.058 billion yuan, a year-on-year decrease of 11.77% [2] - China Merchants Securities reported a net profit of 5.186 billion yuan, a year-on-year increase of 9.23% [2] - Datang Power reported a net profit of approximately 4.874 billion yuan, a year-on-year increase of 50.3% [2] - China Pacific Insurance reported a net profit of 27.885 billion yuan, a year-on-year increase of 11% [2] - Beijing Capital International Airport reported a post-tax loss of 164 million yuan, a year-on-year narrowing of 56.48% [2] - Dongguan Rural Commercial Bank reported a mid-year net profit of 2.629 billion yuan [2] - Shenzhen Holdings reported a mid-year loss attributable to shareholders of 2.618 billion HKD, a year-on-year increase of 137.76% [2] - China Southern Airlines reported a net loss of 1.534 billion yuan, a year-on-year increase of 45.54% [2] - COSCO Shipping Holdings reported a profit attributable to shareholders of 17.528 billion yuan, a year-on-year increase of 3.9% [2] - Guofu Hydrogen Energy reported revenue of 10.9 million yuan, actively expanding overseas cooperation and business layout [2] - Kangsheng Global reported a mid-year gross profit of 197 million yuan, with stable progress across all businesses [2] - Dongfang Electric reported a net profit of 1.91 billion yuan, a year-on-year increase of 12.91%, maintaining the industry's leading market share in nuclear and gas power [2] - Eagle Eye Technology reported a profit of 443,000 yuan, returning to profitability [2] - Haier Smart Home reported a profit attributable to shareholders of 12.033 billion yuan, a year-on-year increase of 15.6% [2] - EDA Group Holdings reached a partnership agreement with UTCPAY to collaborate in digital asset trading, Web3 technology, and blockchain applications [2] - Gilead Sciences reported that ASC30 oral tablets showed good and differentiated pharmacokinetic characteristics in the U.S. Phase Ib multi-dose escalation study [2]

Core Insights - Eagle Eye Technology-B (02251) reported a mid-term performance for the six months ending June 30, 2025, with revenue of 83.713 million RMB, a gross profit of 64.103 million RMB, and a net profit of 0.443 million RMB, marking a turnaround from a loss of 81.488 million RMB in the same period last year [1] Group 1: Financial Performance - Revenue for the reporting period was 83.713 million RMB, with a gross profit of 64.103 million RMB, reflecting a year-on-year increase of 13.53% [1] - The company achieved a net profit of 0.443 million RMB, compared to a loss of 81.488 million RMB in the previous year, indicating a significant turnaround [1] Group 2: Product and Service Expansion - The number of active service points for the retinal detection AI products increased from 5,950 to 7,180, representing a year-on-year growth of 20.7% [1] - The usage of myopia prevention AI products reached 2.812 million times, a year-on-year increase of 68.1%, with the company establishing a distribution service system and star store service system for the PBM-LED myopia treatment device [1] - The visual training AI products recorded 1.026 million training sessions, showing a year-on-year growth of 11.6% [1] Group 3: New Product Development - The company successfully developed and launched a new generation of physiological stress capacity detection product, the "Eagle Eye Stress Capacity Detector," based on wireless sensing technology and multimodal AI algorithms, which has completed product finalization and market testing [1]

Financial Performance - The company reported a revenue of 83.713 million RMB for the six months ending June 30, 2025, with a gross profit of 64.103 million RMB, representing a year-on-year increase of 13.53% [1] - The net profit for the period was 0.443 million RMB, a significant turnaround from a loss of 81.488 million RMB in the same period last year [1] Product and Service Expansion - The number of active service points for the retinal detection AI products increased from 5,950 to 7,180, marking a year-on-year growth of 20.7% [1] - The company detected 3.3 million cases through SaMD and health risk assessment solutions, reflecting an 11.4% year-on-year increase [1] - The usage of myopia prevention AI products reached 2.812 million times, a substantial growth of 68.1% year-on-year [1] - The visual training AI products recorded 1.026 million training sessions, which is an 11.6% increase compared to the previous year [1] New Product Development - The company successfully developed and launched a new generation of physiological stress capacity detection product, the "Eagle Eye Stress Capacity Detector," based on wireless sensing technology and multimodal AI algorithms, which has completed product finalization and market testing [2]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其 準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部分內容而 產生或因倚賴該等內容而引致的任何損失承擔任何責任。 Beijing Airdoc Technology Co., Ltd. 北京鷹瞳科技發展股份有限公司 （於中華人民共和國註冊成立的股份有限公司） （股份代號：2251） 中期業績公告 截至2025年6月30日止六個月 本公司董事會欣然宣佈本集團截至2025年6月30日止六個月的未經審核簡明綜合中期業 績，連同2024年同期的比較數字如下。該等中期業績已經審核委員會及本公司核數師安 永會計師事務所審閱。 於本公告內，「我們」指本公司，及如文義另有所指，指本集團。本公告所載若干金額及 百分比數字已約整，或已四捨五入至小數點後一位或兩位。任何表格、圖表或其他部分 所示總額與所列數額總和的任何差異乃因約整所致。 – 1 – | 財務概要 | | --- | | | 截至6月30日止六個月 | | | --- | --- | --- | | | 2025年 | 2024年 | | | （未經審核） | （未經審核） ...